Human Coagulation Factor V ELISA Kit (DEIA9416)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Species Reactivity
Intended Use
The Human Coagulation Factor V ELISA Kit is intended for the quantitative determination of total Factor V antigen in human plasma.
Contents of Kit
1. 96-well microtiter strip plate (8 x 12 removable wells): Containing anti-human Factor V monoclonal antibody dried and blocked on the surface
2. 10X Wash Buffer: 1 bottle of 50 mL; bring to 1 x using DI water
3. Human Factor V Standard: 1 vial of lyophilized Standard
4. Anti-human Factor V primary antibody: 1 vial of lyophilized monoclonal antibody
5. HRP-streptavidin: 1 vial of concentrated HRP labeled streptavidin
6. TMB substrate solution: 1 bottle of 10 mL solution
All kit components must be stored at 4°C. Store unopened plate and any unused microtiter strips in the pouch with desiccant. Reconstituted standards and primary may be stored at -80°C for later use. DO NOT freeze/thaw the standards and primary antibody more than once. All other unused kit components must be stored at 4°C. Kit should be used no later than the expiration date.


Have you cited DEIA9416 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


An alternative sequential extraction scheme for the determination of trace elements in ferrihydrite rich sediments


Authors: Leermakers, Martine; Mbachou, Bao Elvis; Husson, Angelique; Lagneau, Vincent; Descostes, Michael

Sequential extraction schemes (SES) were evaluated to investigate the fractionation of Al, As, Cd, Cs, Cr, Co, Cu, Fe, Mn, Mo, Pb, Sr, U and Zn between the different mineral phases in iron oxide rich deposits of a former uranium mining site. Ineffective dissolution of iron oxide was observed when applying the BCR sequential extraction scheme. The hydroxylamine hydrochloride reagent in nitric acid could not effectively dissolve the iron oxide phase, even after several consecutive extractions. The use of sodium pyrophosphate to remove organic matter prior to the dissolution of the iron oxides and the use of oxalic acid buffer and dithionite citrate buffer to dissolve the amorphous and crystalline iron oxides was evaluated. An alternative six step SES for iron oxide rich sediments is proposed consisting of F1) Exchangeable-Carbonate fraction using acetic acid/ sodium acetate buffer (pH 5) F2) Labile organic fraction using sodium pyrophosphate, F3) Easily reducible amorphous oxides using an oxalic acid buffer, F4) Organic and Sulfide fraction using hydrogen peroxide, followed by ammonium acetate extraction, F5) Poorly reducible crystalline oxides using sodium dithionite and F6) residual fraction using a microwave digestion step with hydrofluoric acid, nitric acid and hydrochloride acid mixture. A good correspondence between the sum of the sequential extraction steps and total metal concentrations was found. Both the BCR method and new method were also applied to the CRM BCR 701 providing indicative values for non certified elements with the BCR method and indicative values for the method presented.

In vitro anti-pancreatic cancer activity of HPLC-derived fractions from Helicteres hirsuta Lour. stem


Authors: Hong Ngoc Thuy Pham; Quan Van Vuong; Bowyer, Michael C.; Scarlett, Christopher J.

Pancreatic cancer (PC) is one of the leading causes of cancer death in Western societies. The absence of specific symptoms, late diagnosis and the resistance towards chemotherapy result in significant treatment difficulties. As such, it is important to find more effective therapeutic agents for the treatment of PC. Helicteres hirsuta Lour. (H. hirsuta) has been traditionally used in many countries for the treatment of various ailments, indicating that it contains potential therapeutic agents. This study aimed to derive different fractions from the saponin-enriched extract of H. hirsuta stem using RP-HPLC and examine the in vitro anti-pancreatic cancer activity of the derived fractions (F0-F5). With the exception of F0, the five fractions (F1-F5) possessed strong inhibitory activity against PC cells at IC50 values of 3.11-17.12 mu g/mL. The flow cytometry assays revealed the active fractions caused cell cycle arrest at S phase and promoted apoptosis in MIAPaCa-2 PC cells. The LC/MS analysis revealed that the isolated fractions contained bioactive compounds, such as caffeic acid, rosmarinic acid, sagerinic acid, usnic acid, cucurbitacins and absinthin. It can be concluded that the fractions isolated from H. hirsuta stem exhibit potent in vitro anti-pancreatic cancer activity and thus warrant further in vivo studies to assess their activity against PC followed by isolation of individual bioactive compounds and the evaluation of their anti-pancreatic cancer activity.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket